Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

DoW Bone Marrow Failure, Resource Development Award

Active
HT942526BMFRPRDAGrant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The fiscal year 2026 Bone Marrow Failure Research Program Resource Development Award seeks to fund the creation of a comprehensive, open-access multioomic atlas derived from well-annotated human bone marrow failure samples, aiming to accelerate scientific and clinical understanding of these diseases. The initiative requires applicants to generate high-quality genomic, transcriptomic, proteomic, and clinical data integrated into a durable, universally accessible resource, with strict adherence to standardized metadata, data quality control, and robust data security practices. A central requirement is the submission of a detailed Data Resource Sharing Plan and a Sustainment Plan, ensuring the atlas remains available and operational beyond the award period through long-term maintenance strategies and archival in approved biomedical repositories. Applications must also include a Project Narrative, Statement of Work, Technical and Lay Abstracts, Data Management Plan, Impact Statement, and additional supporting documents, all formatted as individual PDFs with precise naming conventions and page limits, with the full application limited to a 12-page narrative, a 5-page SOW, and a 2-page sustainment plan among others. The award has a fixed funding cap of $1,250,000 with a maximum project duration of two years, and all submissions must be made through Grants.gov for extramural applicants or eBRAP for intramural Department of Defense entities, with the full application deadline set for November 4, 2026. Evaluation is based on a two-tier review system combining peer assessment of scientific merit with programmatic review of strategic alignment, emphasizing innovation, team expertise, multidisciplinary collaboration, and the potential for transformative impact on bone marrow failure research. While no formal FAR/DFARS clauses apply, compliance with DoD Instruction 3200.12, CDMRP data sharing directives, and regulatory approvals such as IRB/IACUC is mandatory. The award decision follows a trade-off process, enabling selection based on a balanced consideration of technical excellence, portfolio diversity, and sustainability potential rather than technical score alone. Applicants must maintain an active UEI in SAM.gov, include required representations, and ensure all personnel provide biographical sketches and current/pending support documentation, all of which must comply with federal research integrity and inclusion policies. No physical deliveries or FOB terms are involved; the entire performance scope centers on digital data generation, curation, and dissemination.

General Info

Funding supports creating open-access multiomic atlas from bone marrow failure samples for research.

Agency

Department Of Defense → Defense Health Agency Contracting Activity - DhacaView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(2)

FY26 Bone Marrow Failure Research Program Resource Development Award HT942526BMFRPRDA

PDFfunding-opportunity

FY26 Bone Marrow Failure Research Program Resource Development Award HT942526BMFRPRDA

PDFprogram-announcement

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Defense → Defense Health Agency Contracting Activity - Dhaca
View Agency Profile
Office AddressUSA
Contacts
Christopher L BakerGrants Officer

Full Description

Show more

Summary: The fiscal year 2026 (FY26) Bone Marrow Failure Research Program (BMFRP) Resource Development Award (RDA) supports the development of a multiomic atlas generated from well-annotated human bone marrow failure (BMF) samples, with omic data derived from marrow specimens. The resulting dataset should serve as an open-access, durable resource for the BMF research and clinical communities and is expected to facilitate key discoveries that advance the understanding of BMF diseases.


Distinctive Features: The application must include a robust Data Resource Sharing Plan that describes the means and timeline by which the fully developed resource will be made available to the scientific and clinical community.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

1 day ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Validation and Optimization of ONE-STEP Tagging in Human induced Pluripotent Stem Cells
Solicitation # NIH-NOI-PCA-NIA-01590
The National Institute on Aging (NIA), under the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), has issued a Notice of Intent to Sole Source for the validation and optimization of ONE-STEP tagging in human induced pluripotent stem cells (iPSCs). This acquisition aims to support the iPSC Neurodegenerative Disease Initiative (iNDI) and the Center of Alzheimer’s Disease and Related Dementias (CARD) by generating functionally engineered iPSC lines for research into Alzheimer’s disease and related dementias. The project involves high-activity guide identification, Bxb1 mRNA and cargo plasmid delivery optimization, and the generation of ADRD variant, MAPT 4R, and wild-type process-control clones. All deliverables must be repository-ready, meeting strict quality control standards including long-read sequencing, karyotype analysis, and SNP arrays to ensure scientific continuity and data integrity. The government intends to award this contract to The Jackson Laboratory, citing them as the only responsible source capable of meeting the requirements under FAR 6.302-1 and FAR 13.501(a). This determination is based on the laboratory's unique continuity with the existing iNDI program, established workflows for specific background lines, and proven success in large-scale CRISPR/Cas9 engineering. The total estimated contract value is 3,353,115.00 dollars, covering a base year from September 1, 2026, to August 31, 2027, and an option year extending to August 31, 2028. While this is a sole-source intent, the government will consider capability statements from other sources submitted by August 21, 2026, to determine if adequate competition exists.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 2 days
View Details

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541380
Grant
Molecular and Genomic Laboratory TestingThe contract seeks a subcontractor to conduct advanced molecular and genomic testing on tissue samples from individuals with neurofibromatosis, specifically focusing on next-generation sequencing, RNA sequencing, and other related molecular profiling techniques. The work aims to generate detailed genetic and transcriptomic data to enhance understanding of the disease’s molecular mechanisms, with the expectation that results will support clinical or research initiatives tied to defense health programs. All testing must adhere to high standards of accuracy, reproducibility, and data integrity, with samples received from designated sources and processed under protocols that ensure traceability and quality control. The opportunity is posted under NAICS code 541380, indicating it is classified as other scientific and technical consulting services, and is issued by the Defense Health Agency Contracting Activity under the Department of Defense. Interested parties must submit proposals by the deadline of September 22, 2026, and the work is expected to be performed domestically though the exact location is not specified. The contract does not include set-aside provisions for small businesses or other designated categories, and there is no designated point of contact listed in the posting. Proposals should demonstrate technical expertise in genomic analysis, experience with clinical or research-grade tissue samples, and the capacity to deliver actionable data within stringent timelines.
Testing Laboratories and Services

POSTED

about 2 months ago

DEADLINE

in about 1 month
View Details
NAICS: 541611
Grant
Clinical Trial Design and Biostatistical SupportThe contract seeks a subcontractor to provide comprehensive biostatistical consulting services in support of clinical and translational research initiatives, with a focus on study design, power analysis, randomization procedures, and the development of robust data analysis plans. The work is intended to ensure methodological rigor and statistical validity across defense-related health research projects, requiring expertise in applying statistical principles to real-world clinical trial scenarios. The contractor must be capable of tailoring statistical methodologies to the unique constraints and objectives of military and veteran health research environments. This opportunity is issued under the Defense Health Agency Contracting Activity, operating within the Department of Defense, and is classified under NAICS code 541611 for scientific research and development services. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026. Performance location details are not specified, indicating potential flexibility in execution, though the work must align with the Agency’s operational and research priorities. As a subcontract, this engagement is likely part of a larger research initiative, and proposers should be prepared to collaborate effectively with primary contractors and federal research teams to deliver timely, high-quality statistical support.
Administrative Management and General Management Consulting Services

POSTED

about 2 months ago

DEADLINE

in about 1 month
View Details
NAICS: 541711
Grant
Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.
Research and Development in Biotechnology

POSTED

about 2 months ago

DEADLINE

in about 1 month
View Details